Deferasirox pharmacokinetic and toxicity correlation in β‐thalassaemia major treatment. (27th September 2016)

• Record Type: Journal Article
• Authors: Allegra, Sarah; De Francia, Silvia; Cusato, Jessica; Pirro, Elisa; Massano, Davide; Piga, Antonio; D'Avolio, Antonio
• Is Part Of: Journal of pharmacy and pharmacology. Volume 68:Number 11(2016:Nov.)
• Page Start: 1417
• Page End: 1421
• Publication Date: 2016-09-27
• Subjects: Exjade® -- iron chelation -- iron overload -- thalassaemia -- therapeutic drug monitoring; Pharmacy -- Periodicals; Pharmacology -- Periodicals; 615.1
• DOI: 10.1111/jphp.12638
• Languages: English
• ISSNs: 0022-3573

Abstract

Abstract: Objectives: Deferasirox adverse effects include the following: gastrointestinal disturbance, mild elevations in serum creatinine levels and intermittent proteinuria; these events are dose‐dependent and reversible with drug discontinuation, but this solution can lead to an inadequate iron chelation. For these reasons, interindividual variability of drug plasma concentration could help the clinical management of deferasirox dosage. We sought to describe deferasirox plasma exposure in a cohort of 60 adult patients. Methods: A fully validated chromatographic method was used to quantify deferasirox concentration in plasma collected from β‐thalassaemia adult patients. Samples obtained before and after 2, 4, 6 and 24 h drug administration were evaluated. Associations between variables were tested using the Pearson test. Key findings: Concerning pharmacokinetic parameters, a higher interindividual variability was shown. A positive correlation was found between deferasirox area under the concentration curve over 24 h and serum creatinine ( r = 0.314; P = 0.018) and between area and drug dose ( r = 0.311; P = 0.016). Moreover, a negative correlation resulted among area under the concentration curve over 24 h and serum ferritin ( r = −0.291; P = 0.026) and among drug half‐life and its dose ( r = −0.319; P = 0.013). Conclusions: Treatment decision based on the individual characteristics could strongly contribute to minimize toxicity and increase efficacy of deferasirox therapy.